Molecular basis of antibody binding to mucin glycopeptides in lung cancer

Qu,Jin; Yu,Hongtao; Li,Fenge; Zhang,Chunlei; Trad,Ahmad; Brooks,Cory; Zhang,Bin; Gong,Ting; Guo,Zhi; Li,Yunsen; Ragupathi,Govind; Lou,Yanyan; Hwu,Patrick; Huang,Wei; Zhou,Dapeng

doi:10.3892/ijo.2015.3302

Molecular basis of antibody binding to mucin glycopeptides in lung cancer

Authors:
- Jin Qu
- Hongtao Yu
- Fenge Li
- Chunlei Zhang
- Ahmad Trad
- Cory Brooks
- Bin Zhang
- Ting Gong
- Zhi Guo
- Yunsen Li
- Govind Ragupathi
- Yanyan Lou
- Patrick Hwu
- Wei Huang
- Dapeng Zhou
View Affiliations

Affiliations: Shanghai Pulmonary Hospital Affiliated with Tongji University School of Medicine, Shanghai 200092, P.R. China, CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and iHuman Institute, Shanghai Tech University, Shanghai 201203, P.R. China, Tianjin Cancer Hospital, Tianjin 300060, P.R. China, Shenzhen Hospital of Chinese Medicine, Shenzhen, Guangdong 518033, P.R. China, Biochemical Institute, Medical Faculty, Christian-Albrechts-University of Kiel, 24105 Kiel, Germany, Department of Chemistry, California State University, Fresno, CA 93740, USA, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA, Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Smithville, TX 78957, USA, Laboratory of Cellular and Molecular Tumor Immunology, Jiangsu Key Laboratory of Infection and Immunity, Institutes of Biology and Medical Sciences, Soochow University, Suzhou, Jiangsu 215123, P.R. China, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA, Mayo Clinic, Jacksonville, FL 32224, USA, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Published online on: December 18, 2015 https://doi.org/10.3892/ijo.2015.3302
Pages: 587-594

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glycopeptides bearing Tn epitopes are emerging targets for cancer diagnosis and immunotherapy. In this study, we analyzed membrane proteins containing O-glycosylated tandem repeat (TR) sequences in lung cancer patients of different types and stages, using gene microarray data in public domain. The expression of Tn and glycopeptide epitopes on the surface of lung cancer cell lines were studied by monoclonal IgG antibodies 14A, 16A, and B72.3. The binding of mAbs to synthetic glycopeptides were studied by surface plasmon resonance. Nine mucin mRNAs were found to be expressed in lung cancer patients but at similar level to healthy individuals. At protein level, a glycopeptide epitope on cancer cell surface is preferably recognized by mAb 16A, as compared to peptide-alone (14A) or sugar-alone epitopes (B72.3). 14A and 16A favor clustered TR containing more than three TR sequences, with 10-fold lower Kd than two consecutive TR. B72.3 preferrably recognized clustered sialyl-Tn displayed on MUC1 but not other O-glycoproteins, with 100-fold stronger binding when MUC1 is transfected as a sugar carrier, while the total sugar epitopes remain unchanged. These findings indicate that clusters of both TR backbones and sugars are essential for mAb binding to mucin glycopeptides. Three rules of antibody binding to mucin glycopeptides at molecular level are presented here: first, the peptide backbone of a glycopeptide is preferentially recognized by B cells through mutations in complementarity determining regions (CDRs) of B cell receptor, and the sugar-binding specificity is acquired through mutations in frame work of heavy chain; secondly, consecutive tandem repeats (TR) of peptides and glycopeptides are preferentially recognized by B cells, which favor clustered TR containing more than three TR sequences; thirdly, certain sugar-specific B cells recognize and accommodate clustered Tn and sialyl-Tn displayed on the surface of a mucin but not other membrane proteins.

View Figures

View References

1	Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al: Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 369:134–144. 2013. View Article : Google Scholar : PubMed/NCBI
2	Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 366:2455–2465. 2012. View Article : Google Scholar : PubMed/NCBI
3	Ahmad R, Alam M, Rajabi H and Kufe D: The MUC1-C oncoprotein binds to the BH3 domain of the pro-apoptotic BAX protein and blocks BAX function. J Biol Chem. 287:20866–20875. 2012. View Article : Google Scholar : PubMed/NCBI
4	Xu X, Wells A, Padilla MT, Kato K, Kim KC and Lin Y: A signaling pathway consisting of miR-551b, catalase and MUC1 contributes to acquired apoptosis resistance and chemoresistance. Carcinogenesis. 35:2457–2466. 2014. View Article : Google Scholar : PubMed/NCBI
5	Zhang K, Sikut R and Hansson GC: A MUC1 mucin secreted from a colon carcinoma cell line inhibits target cell lysis by natural killer cells. Cell Immunol. 176:158–165. 1997. View Article : Google Scholar : PubMed/NCBI
6	Ogata S, Maimonis PJ and Itzkowitz SH: Mucins bearing the cancer-associated sialosyl-Tn antigen mediate inhibition of natural killer cell cytotoxicity. Cancer Res. 52:4741–4746. 1992.PubMed/NCBI
7	Moreno M, Bontkes HJ, Scheper RJ, Kenemans P, Verheijen RH and von Mensdorff-Pouilly S: High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC). Cancer Lett. 257:47–55. 2007. View Article : Google Scholar : PubMed/NCBI
8	Belisle JA, Horibata S, Jennifer GA, Petrie S, Kapur A, André S, Gabius HJ, Rancourt C, Connor J, Paulson JC, et al: Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes. Mol Cancer. 9:1182010. View Article : Google Scholar : PubMed/NCBI
9	Kuemmel A, Single K, Bittinger F, Faldum A, Schmidt LH, Sebastian M, Micke P, Taube C, Buhl R and Wiewrodt R: TA-MUC1 epitope in non-small cell lung cancer. Lung Cancer. 63:98–105. 2009. View Article : Google Scholar
10	Devine PL, Birrell GW, Quin RJ and Shield PW: Monoclonal antibodies recognising sialyl-Tn: Production and application to immunochemistry. Dis Markers. 12:175–186. 1995. View Article : Google Scholar : PubMed/NCBI
11	Longenecker BM, Willans DJ, MacLean GD, Selvaraj S, Suresh MR and Noujaim AA: Monoclonal antibodies and synthetic tumor-associated glycoconjugates in the study of the expression of Thomsen-Friedenreich-like and Tn-like antigens on human cancers. J Natl Cancer Inst. 78:489–496. 1987.PubMed/NCBI
12	Nguyen PL, Niehans GA, Cherwitz DL, Kim YS and Ho SB: Membrane-bound (MUC1) and secretory (MUC2, MUC3, and MUC4) mucin gene expression in human lung cancer. Tumour Biol. 17:176–192. 1996. View Article : Google Scholar : PubMed/NCBI
13	Snijdewint FG, von Mensdorff-Pouilly S, Karuntu-Wanamarta AH, Verstraeten AA, Livingston PO, Hilgers J and Kenemans P: Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients. Int J Cancer. 93:97–106. 2001. View Article : Google Scholar : PubMed/NCBI
14	Vassilaros S, Tsibanis A, Tsikkinis A, Pietersz GA, McKenzie IF and Apostolopoulos V: Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan-MUC1. Immunotherapy. 5:1177–1182. 2013. View Article : Google Scholar : PubMed/NCBI
15	Kimura T, McKolanis JR, Dzubinski LA, Islam K, Potter DM, Salazar AM, Schoen RE and Finn OJ: MUC1 vaccine for individuals with advanced adenoma of the colon: A cancer immunoprevention feasibility study. Cancer Prev Res (Phila). 6:18–26. 2013. View Article : Google Scholar
16	Ramanathan RK, Lee KM, McKolanis J, Hitbold E, Schraut W, Moser AJ, Warnick E, Whiteside T, Osborne J, Kim H, et al: Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol Immunother. 54:254–264. 2005. View Article : Google Scholar
17	Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, Eschrich S, Jurisica I, Giordano TJ, Misek DE, et al; Director's Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma. Gene expression-based survival prediction in lung adenocarcinoma: A multi-site, blinded validation study. Nat Med. 14:822–827. 2008. View Article : Google Scholar : PubMed/NCBI
18	Wilson CL and Miller CJ: Simpleaffy: A BioConductor package for Affymetrix Quality Control and data analysis. Bioinformatics. 21:3683–3685. 2005. View Article : Google Scholar : PubMed/NCBI
19	Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, Ladd C, Beheshti J, Bueno R, Gillette M, et al: Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA. 98:13790–13795. 2001. View Article : Google Scholar : PubMed/NCBI
20	Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B and Speed TP: Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 31:e152003. View Article : Google Scholar : PubMed/NCBI
21	R Development Core Team. R: A Language and Environment for Statistical Computing: the R Foundation for Statistical Computing. Vienna: 2011
22	Song W, Delyria ES, Chen J, Huang W, Lee JS, Mittendorf EA, Ibrahim N, Radvanyi LG, Li Y, Lu H, et al: MUC1 glycopeptide epitopes predicted by computational glycomics. Int J Oncol. 41:1977–1984. 2012.PubMed/NCBI
23	Reddish MA, Jackson L, Koganty RR, Qiu D, Hong W and Longenecker BM: Specificities of anti-sialyl-Tn and anti-Tn monoclonal antibodies generated using novel clustered synthetic glycopeptide epitopes. Glycoconj J. 14:549–560. 1997. View Article : Google Scholar : PubMed/NCBI
24	Colcher D, Hand PH, Nuti M and Schlom J: A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci USA. 78:3199–3203. 1981. View Article : Google Scholar : PubMed/NCBI
25	Schietinger A, Philip M, Yoshida BA, Azadi P, Liu H, Meredith SC and Schreiber H: A mutant chaperone converts a wild-type protein into a tumor-specific antigen. Science. 314:304–308. 2006. View Article : Google Scholar : PubMed/NCBI
26	Vierbuchen MJ, Fruechtnicht W, Brackrock S, Krause KT and Zienkiewicz TJ: Quantitative lectin-histochemical and immunohistochemical studies on the occurrence of alpha(2,3)- and alpha(2,6)-linked sialic acid residues in colorectal carcinomas. Relation to clinicopathologic features. Cancer. 76:727–735. 1995. View Article : Google Scholar : PubMed/NCBI
27	Steentoft C, Vakhrushev SY, Joshi HJ, Kong Y, Vester-Christensen MB, Schjoldager KT, Lavrsen K, Dabelsteen S, Pedersen NB, Marcos-Silva L, et al: Precision mapping of the human O-GalNAc glycoproteome through SimpleCell technology. EMBO J. 32:1478–1488. 2013. View Article : Google Scholar : PubMed/NCBI
28	Yang Z, Halim A, Narimatsu Y, Jitendra Joshi H, Steentoft C, Schjoldager KT, Alder Schulz M, Sealover NR, Kayser KJ, Paul Bennett E, et al: The GalNAc-type O-Glycoproteome of CHO cells characterized by the SimpleCell strategy. Mol Cell Proteomics. 13:3224–3235. 2014. View Article : Google Scholar : PubMed/NCBI
29	Levery SB, Steentoft C, Halim A, Narimatsu Y, Clausen H and Vakhrushev SY: Advances in mass spectrometry driven O-glycoproteomics. Biochim Biophys Acta. 1850.33–42. 2015.
30	Lakshminarayanan V, Thompson P, Wolfert MA, Buskas T, Bradley JM, Pathangey LB, Madsen CS, Cohen PA, Gendler SJ and Boons GJ: Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine. Proc Natl Acad Sci USA. 109:261–266. 2012. View Article : Google Scholar :
31	Dokurno P, Bates PA, Band HA, Stewart LM, Lally JM, Burchell JM, Taylor-Papadimitriou J, Snary D, Sternberg MJ and Freemont PS: Crystal structure at 1.95 A resolution of the breast tumour-specific antibody SM3 complexed with its peptide epitope reveals novel hypervariable loop recognition. J Mol Biol. 284:713–728. 1998. View Article : Google Scholar : PubMed/NCBI
32	Möller H, Serttas N, Paulsen H, Burchell JM, Taylor-Papadimitriou J and Meyer Bernd: NMR-based determination of the binding epitope and conformational analysis of MUC-1 glycopeptides and peptides bound to the breast cancer-selective monoclonal antibody SM3. Eur J Biochem. 269:1444–1455. 2002. View Article : Google Scholar : PubMed/NCBI
33	Spencer DI, Missailidis S, Denton G, Murray A, Brady K, Matteis CI, Searle MS, Tendler SJ and Price MR: Structure/activity studies of the anti-MUC1 monoclonal antibody C595 and synthetic MUC1 mucin-core-related peptides and glycopeptides. Biospectroscopy. 5:79–91. 1999. View Article : Google Scholar : PubMed/NCBI
34	Matsumoto-Takasaki A, Hanashima S, Aoki A, Yuasa N, Ogawa H, Sato R, Kawakami H, Mizuno M, Nakada H, Yamaguchi Y, et al: Surface plasmon resonance and NMR analyses of anti Tn-antigen MLS128 monoclonal antibody binding to two or three consecutive Tn-antigen clusters. J Biochem. 151:273–282. 2012. View Article : Google Scholar
35	Ibrahim NK, Murray JL, Zhou D, Mittendorf EA, Sample D, Tautchin M and Miles D: Survival Advantage in Patients with Metastatic Breast Cancer Receiving Endocrine Therapy plus Sialyl Tn-KLH Vaccine: Post Hoc Analysis of a Large Randomized Trial. J Cancer. 4:577–584. 2013. View Article : Google Scholar : PubMed/NCBI
36	Forsström B, Axnäs BB, Stengele KP, Bühler J, Albert TJ, Richmond TA, Hu FJ, Nilsson P, Hudson EP, Rockberg J, et al: Proteome-wide epitope mapping of antibodies using ultra-dense peptide arrays. Mol Cell Proteomics. 13:1585–1597. 2014. View Article : Google Scholar : PubMed/NCBI